Jeff Garro Analyst PerformanceManaging Director at StephensJeff Garro is a stock analyst at Stephens across a range of sectors, covering 11 publicly traded companies. Over the past year, Jeff Garro has issued 17 stock ratings, including buy and hold recommendations. While full access to Jeff Garro's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jeff Garro's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings25 Last 4 YearsBuy Recommendations44.00% 11 Buy RatingsCompanies Covered11 Unique Companies Ratings Distribution25RatingsDistribution of strong buy, buy, hold, and sell ratings by Jeff Garro.RatingPercentageCount Strong Buy0.0%0 ratings Buy44.0%11 ratings Hold56.0%14 ratings Sell0.0%0 ratingsOut of 25 total stock ratings issued by Jeff Garro at Stephens, the majority (56.0%) have been Hold recommendations, followed by 44.0% Buy.Best & Worst CallsBest Call000.0%CERTFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%SLQTAug 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ72.7% of companies on NASDAQ8 companiesNYSE27.3% of companies on NYSE3 companiesJeff Garro, an analyst at Stephens, currently covers 11 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical5 companies45.5%Computer and Technology4 companies36.4%Business Services1 company9.1%Finance1 company9.1%Jeff Garro of Stephens specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology and Business Services companies.Coverage IndustriesIndustryPercentageMEDICAL INFO SYS4 companies36.4%COMP - SOFTWARE2 companies18.2%INTERNET SOFTWARE2 companies18.2%MED - BIOMED/GENE1 company9.1%COMPUTER INTEGRATED SYSTEMS DESIGN1 company9.1%INS - MULTI LINE1 company9.1% About Jeff GarroJeff Garro, CFA is a Managing Director and equity research analyst covering Healthcare IT. Jeff joined Stephens in September 2022 from previous research analyst roles at Piper Sandler, and William Blair, and has covered healthcare IT stocks since 2009. Prior to equity research, Jeff worked as a litigation attorney. Jeff received his B.S.E. in Biomedical and Electrical Engineering from Duke University in 2004 and his J.D. from DePaul University in 2007.Follow on LinkedIn Jeff Garro's Ratings History at Stephens Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsOPRXOptimizeRx5/13/2026Lower Price Target$4.86$7.00Equal Weight$0.0000.00% ROICERTCertara5/12/2026Lower Price Target$5.02$9.00Overweight$0.0000.00% ROIHCATHealth Catalyst5/12/2026Lower Price Target$1.44$1.75Equal Weight$0.0000.00% ROITBRGTruBridge4/1/2026Lower Price Target$16.10$18.00Equal Weight$0.0000.00% ROIPHRPhreesia3/31/2026Lower Price Target$11.43$20.00Overweight$0.0000.00% ROIHCATHealth Catalyst3/13/2026Lower Price Target$1.39$2.00Equal Weight$0.0000.00% ROIOPRXOptimizeRx3/6/2026Lower Price Target$6.30$10.00Equal Weight$0.0000.00% ROIDHDefinitive Healthcare2/27/2026Lower Price Target$1.21$2.00Equal Weight$0.0000.00% ROICERTCertara12/12/2025Lower Price Target$8.81$12.00Overweight$0.0000.00% ROIPRVAPrivia Health Group12/4/2025Reiterated Rating$24.27$32.00Overweight$0.0000.00% ROIOPRXOptimizeRx11/17/2025Lower Price Target$15.18$17.00Equal Weight$0.0000.00% ROIEVHEvolent Health11/13/2025Upgrade$4.55$7.00Overweight$0.0000.00% ROIPRVAPrivia Health Group9/24/2025Reiterated Rating$23.48$32.00Overweight$0.0000.00% ROIEVHEvolent Health9/24/2025Reiterated Rating$8.41$9.00Equal Weight$0.0000.00% ROIPRVAPrivia Health Group9/4/2025Reiterated Rating$23.17$32.00Overweight$0.0000.00% ROIPHRPhreesia9/3/2025Reiterated Rating$31.47$32.00Overweight$0.0000.00% ROISLPSimulations Plus7/15/2025Lower Price Target$17.47$20.00Overweight$0.0000.00% ROITBRGTruBridge4/10/2025Reiterated Rating$25.87$28.00Equal Weight$00.0000.00% ROITBRGTruBridge3/11/2025Boost Price Target$30.55$28.00Equal Weight$00.0000.00% ROIHCATHealth Catalyst3/6/2025Lower Price Target$4.52$5.00Equal Weight$0.0000.00% ROIHCATHealth Catalyst2/27/2025Reiterated Rating$4.13$7.00Equal Weight$0.0000.00% ROICERTCertara2/27/2025Reiterated Rating$12.39$17.00Overweight$0.0000.00% ROIMDRXVeradigm1/31/2025Boost Price Target$4.78$13.00Equal Weight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
